Another parker reply
My whole point this entire time was that the MMs are short big time and they will eventually have to buy it back. They can be patient and collect every weak share but no matter what they have to buy back a lot of shares. I think the last explosion was because the MMs were buying it back. There are many things that the company is working on that will warrant news such as seethruequity info, animal study results, possible analysis studies from the rats being used in the study, and data from the university study. Propanc is a special company, I have never worked with a company that has such incredible opportunities. That said it is a spec play but it keep in mind the company already has efficacy data from the compassionate care study. In the arena that Propanc is in should PRP extend life by only a couple months then it's a billion dollar revenue drug on the low end.
Sent from my iPhone
News 
Market Data 
Discover 
